JP2008520747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520747A5 JP2008520747A5 JP2007543475A JP2007543475A JP2008520747A5 JP 2008520747 A5 JP2008520747 A5 JP 2008520747A5 JP 2007543475 A JP2007543475 A JP 2007543475A JP 2007543475 A JP2007543475 A JP 2007543475A JP 2008520747 A5 JP2008520747 A5 JP 2008520747A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- ischemic
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 208000023589 ischemic disease Diseases 0.000 claims 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 3
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 3
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000012113 pregnancy disease Diseases 0.000 claims 2
- XTPOZVLRZZIEBW-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC(N)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XTPOZVLRZZIEBW-SCFUHWHPSA-N 0.000 claims 1
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 claims 1
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 claims 1
- 125000003853 4-amino-3-iodobenzyl group Chemical group [H]N([H])C1=C(I)C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 1
- 206010070531 Foetal growth restriction Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 239000002593 adenosine A3 receptor agonist Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030941 fetal growth restriction Diseases 0.000 claims 1
- -1 heteroallyl Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Claims (14)
- (N6−(4−アミノ−3−ヨードベンジル)−アデノシン−5‘−N−メチルウロナミド)(AB−MECA)、N6−2−(4−アミノフェニル)エチル−アデノシン(APNEA)、(N6−(3−ヨードベンジル)−5’−N−メチルカルボキサミドアデノシン)(IB−MECA)、2−クロロ−IB−MECA、及び
次の式:
Arはアリル基であり;
RとR1は、それぞれ独立して、水素、アルキル、アリル、置換アルキル、置換アリル、ヘテロアリル、アルケニル、置換アルケニル、シクロアルケニル、置換シクロアルケニル、シクロアルキル、置換シクロアルキル、アルコキシ、置換アルコキシ、アルキニル又は置換アルキニルである;又は
RとR1が、結合している窒素原子と一緒になって、O、S及びNから選択される1〜4のヘテロ原子をさらに含んでいてもよい単環又は複数の縮合環を有する、置換又は非置換、飽和又は不飽和の3〜20員環系を形成してもよい)
で表される化合物;
又は薬学的に許容可能なその塩である)
で表される化合物より選択される、HIF−1α(低酸素誘導因子1−α)の発現レベルを上昇させる作用を有し、それにより虚血性の組織障害を軽減させるアデノシンA3受容体アゴニストを含有してなる、HIF−αの発現レベルの低下により特徴付けられる虚血性疾患における血管新生を促進するための医薬組成物。 - HIF−1αの発現が少なくとも10%増大する、請求項1に記載の医薬組成物。
- HIF−1αの発現が少なくとも30%増大する、請求項1に記載の医薬組成物。
- HIF−1αの発現が少なくとも60%増大する、請求項1に記載の医薬組成物。
- 虚血性疾患が、肺高血圧症である、請求項1に記載の医薬組成物。
- 虚血性疾患が虚血性心血管疾患である、請求項5に記載の医薬組成物。
- 虚血性心血管疾患が、心筋虚血又は心筋梗塞である、請求項6に記載の医薬組成物。
- 虚血性疾患が、末梢性動脈病、深部静脈血栓症又は血管不全である、請求項5に記載の医薬組成物。
- 虚血性疾患が妊娠疾患である、請求項5に記載の医薬組成物。
- 妊娠疾患が、子癇前症又は子宮内発育遅延である、請求項9に記載の医薬組成物。
- 虚血性疾患が、発作又は多梗塞性認知症である、請求項1に記載の医薬組成物。
- 虚血性疾患が末梢性動脈病である、請求項1に記載の医薬組成物。
- 末梢性動脈病が壊疽である、請求項12に記載の医薬組成物。
- 虚血性疾患が、脳虚血又は網膜虚血である、請求項1に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63055504P | 2004-11-22 | 2004-11-22 | |
PCT/US2005/042552 WO2006055970A2 (en) | 2004-11-22 | 2005-11-22 | Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008520747A JP2008520747A (ja) | 2008-06-19 |
JP2008520747A5 true JP2008520747A5 (ja) | 2008-12-25 |
Family
ID=36407882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007543475A Withdrawn JP2008520747A (ja) | 2004-11-22 | 2005-11-22 | アデノシンa3受容体アゴニストを用いたhif−1が介在する疾患の促進的治療 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20060204502A1 (ja) |
EP (1) | EP1819349A2 (ja) |
JP (1) | JP2008520747A (ja) |
CN (1) | CN101083998A (ja) |
AU (1) | AU2005306325A1 (ja) |
CA (1) | CA2585581A1 (ja) |
IL (1) | IL183310A0 (ja) |
WO (1) | WO2006055970A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060074182A1 (en) * | 2004-09-30 | 2006-04-06 | Depuy Products, Inc. | Hydrogel composition and methods for making the same |
WO2007002139A2 (en) * | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection of retinal ganglion cells |
ES2360632T3 (es) * | 2006-01-26 | 2011-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Moduladores alostéricos del receptor a3 de adenosina. |
CN101420980A (zh) | 2006-02-16 | 2009-04-29 | 菲布罗根公司 | 治疗中风的化合物和方法 |
EP2084527A4 (en) * | 2006-11-02 | 2011-07-27 | Seattle Genetics Inc | METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES |
JP5592262B2 (ja) * | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
WO2010005527A1 (en) * | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
WO2010009190A1 (en) * | 2008-07-16 | 2010-01-21 | King Pharmaceuticals Research And Development, Inc. | Methods of treating atherosclerosis |
JP2011528364A (ja) * | 2008-07-16 | 2011-11-17 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アテローム性動脈硬化症の治療 |
ES2422872T3 (es) * | 2008-08-19 | 2013-09-16 | Universiteit Leiden | Moduladores alostéricos del receptor de adenosina A3 |
KR20120022919A (ko) | 2009-05-17 | 2012-03-12 | 캔-파이트 바이오파마 리미티드 | 안압의 감소를 위한 a3 아데노신 수용체 작동제 |
FR3043555B1 (fr) * | 2015-11-17 | 2019-10-25 | Centre National De La Recherche Scientifique (Cnrs) | Mirabegron pour le traitement de maladies retiniennes |
CN110248956B (zh) * | 2016-10-11 | 2023-02-21 | 奥利通公司 | HIF-1α反义寡核苷酸 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554336A (en) * | 1984-08-08 | 1996-09-10 | 3D Systems, Inc. | Method and apparatus for production of three-dimensional objects by stereolithography |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5443836A (en) * | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
US6210917B1 (en) * | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
CA2289731A1 (en) * | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
US6329349B1 (en) * | 1997-10-23 | 2001-12-11 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents |
US6326390B1 (en) * | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
US6921825B2 (en) * | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
US20030166605A1 (en) * | 1999-04-27 | 2003-09-04 | Edward Leung | Method of minimizing damage to heart tissue during cardiac surgery and cardiac transplantation |
US6803457B1 (en) * | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
GB0013655D0 (en) * | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
ATE292973T1 (de) * | 2001-01-16 | 2005-04-15 | Can Fite Biopharma Ltd | Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation |
US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
US20040204481A1 (en) * | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
US20030078232A1 (en) * | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
US7262176B2 (en) * | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
US20030143282A1 (en) * | 2002-01-28 | 2003-07-31 | Pnina Fishman | Adenosine A3 receptor agonist |
JP2005532260A (ja) * | 2002-01-29 | 2005-10-27 | コグネティックス・インコーポレイテッド | 器官保護剤としてのカッパ−pviia−関連コノトキシン |
US20040067932A1 (en) * | 2002-06-24 | 2004-04-08 | Borea Pier Andrea | Enhancing treatment of MDR cancer with adenosine A3 antagonists |
DE60330250D1 (de) * | 2002-09-09 | 2010-01-07 | Cv Therapeutics Inc | Adenosin a3 rezeptor agonisten |
EP1682115A4 (en) * | 2003-11-07 | 2010-07-28 | Univ Emory | HIF-1 HEMMER AND APPLICATION METHOD THEREFOR |
-
2005
- 2005-11-22 CN CNA2005800400361A patent/CN101083998A/zh active Pending
- 2005-11-22 WO PCT/US2005/042552 patent/WO2006055970A2/en active Application Filing
- 2005-11-22 AU AU2005306325A patent/AU2005306325A1/en not_active Abandoned
- 2005-11-22 JP JP2007543475A patent/JP2008520747A/ja not_active Withdrawn
- 2005-11-22 US US11/286,127 patent/US20060204502A1/en not_active Abandoned
- 2005-11-22 CA CA002585581A patent/CA2585581A1/en not_active Abandoned
- 2005-11-22 US US11/286,129 patent/US20060194756A1/en not_active Abandoned
- 2005-11-22 EP EP05852103A patent/EP1819349A2/en not_active Withdrawn
-
2007
- 2007-05-17 IL IL183310A patent/IL183310A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008520747A5 (ja) | ||
JP2010536761A5 (ja) | ||
JP2017528503A5 (ja) | ||
JP2019513694A (ja) | 血液学的悪性腫瘍及び固形腫瘍の治療のためのidh2阻害剤 | |
JP2015503527A5 (ja) | ||
JP2002322193A (ja) | 虚血の治療のための化合物 | |
RU2014150338A (ru) | Соединение как ингибитор передачи сигналов wnt, его композиции и применение | |
JP2014502979A5 (ja) | ||
JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプIII(PDEIII)インヒビターまたはCa2+感作剤 | |
JP2019518779A5 (ja) | ||
US20230000835A1 (en) | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms | |
CA2784908A1 (en) | Combination, kit and method of reducing intraocular pressure | |
Henriksson et al. | Prostacyclin infusion in patients with acute myocardial infarction. | |
JP4705564B2 (ja) | 洞房結節If電流阻害剤およびアンギオテンシン変換酵素阻害剤の新規な組み合わせならびにそれを含む医薬組成物 | |
JP2010518154A5 (ja) | ||
WO2021187548A1 (ja) | 慢性心不全の治療又は予防方法 | |
JPH10505593A (ja) | 抗ウイルス剤としての4−(2−アミノ−6−(シクロプロピルアミノ)−9h−プリン−9−イル)−2−シクロペンテン−1−メタノールのコハク酸塩 | |
EP2855424B1 (en) | Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide | |
JP2012533574A (ja) | 心筋虚血を予防および治療する薬物の調製における低分子量ペプチドmlifの使用 | |
WO2015116782A1 (en) | Nucleobase analogue derivatives and their applications | |
US20230032813A1 (en) | Methods of treating pulmonary arterial hypertension | |
JP2008169213A (ja) | 内皮機能不全の処置を目的とする医薬を製造するためのイバブラジンの使用 | |
US20070281947A1 (en) | Diarylmethylpiperazines As Prophylactic Or Therapeutic Agents For Viral Myocarditis | |
JP4380967B2 (ja) | ウイルス性心筋炎の予防または治療剤 | |
EP1812006A2 (en) | Methods of using pde v inhibitors for the treatment of congestive heart failure |